CoChat

Positive modulators of the α7 nicotinic receptor against neuroinflammation and cognitive impairment in Alzheimer's disease

Open access
Echeverria, Valentina, Yarkov, Alex, Aliev, Gjumrakch · 2016 · Progress in Neurobiology
Cited by 91

The DOI matches its Crossref record; 63 of the 63 references it cites were found in a registry or an index.

Abstract

Evidence so far indicates that therapies targeting a single aspect of Alzheimer's disease (AD) have no sufficient efficacy in diminishing long-term the progression of AD. Neuroinflammation is an early event during the development of the disease and it is thought to exacerbate the abnormal aggregation of the amyloid beta peptide (Aβ) and the microtubule associated protein Tau. Inhibition of gliosis is considered fundamental to reduce neuroinflammation, oxidative stress, apoptosis and synaptic dysfunction driving the progression of AD. Drugs that are able to target more than one aspect of the pathology may have higher chances of success. Modulators of α7 nicotinic acetylcholine receptors (α7nAChRs) such as nicotine and some of its derivatives have this potential because of their anti-inflammatory, anti-apoptotic, pro-cognitive and anti-protein aggregation effects. However, the rapid desensitization of α7nAChRs is considered an important factor limiting its potential therapeutic use. In here, in light of current evidence, the objective of this review is to discuss the advantages and potential therapeutic value of positive allosteric modulators (PAMs) of the nAChRs in halting or delaying the progression of AD by diminishing neuroinflammation, abnormal protein aggregation and synaptic dysfunction.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.pneurobio.2016.01.002

Cites

63 of 63 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 63 references

Research works printed but not linked: 183

  1. Abdul, 2009, Cognitive decline in Alzheimer's disease is associated with selective changes in calcineurin/NFAT signaling, J. Neurosci., 29, 12957, 10.1523/JNEUROSCI.1064-09.2009 · DOI · Paper page
  2. Ahmad, 2006, Stimulation of prostaglandin EP2 receptors prevents NMDA-induced excitotoxicity, J. Neurotrauma, 23, 1895, 10.1089/neu.2006.23.1895 · DOI
  3. Ahmad, 2006, 1-hydroxyPGE reduces infarction volume in mouse transient cerebral ischemia, Eur. J. Neurosci., 23, 35, 10.1111/j.1460-9568.2005.04540.x · DOI
  4. Akiyama, 2000, Inflammation and Alzheimer's disease, Neurobiol. Aging, 21, 383, 10.1016/S0197-4580(00)00124-X · DOI · Paper page
  5. Aliev, 2003, Hypoperfusion, mitochondria failure, oxidative stress, and alzheimer disease, J. Biomed. Biotechnol., 2003, 162, 10.1155/S1110724303305029 · DOI
  6. Alkadhi, 2011, Chronic psychosocial stress exacerbates impairment of synaptic plasticity in beta-amyloid rat model of Alzheimer's disease: prevention by nicotine, Curr. Alzheimer Res., 8, 718, 10.2174/156720511797633188 · DOI · Paper page
  7. Alkadhi, 2010, Intensification of long-term memory deficit by chronic stress and prevention by nicotine in a rat model of Alzheimer's disease, Mol. Cell Neurosci., 45, 289, 10.1016/j.mcn.2010.06.018 · DOI
  8. Amin, 2014, Effect of Abeta immunisation on hyperphosphorylated tau: a potential role for GSK-3beta, Neuropathol. Appl. Neurobiol., 41, 445, 10.1111/nan.12205 · DOI
  9. Appel, 1981, A unifying hypothesis for the cause of amyotrophic lateral sclerosis, parkinsonism, and Alzheimer disease, Ann. Neurol., 10, 499, 10.1002/ana.410100602 · DOI · Paper page
  10. Aronson, 2009, Optimal dosing of galantamine in patients with mild or moderate Alzheimer's disease: post Hoc analysis of a randomized, double-blind, placebo-controlled trial, Drugs Aging, 26, 231, 10.2165/00002512-200926030-00004 · DOI
  11. Association, 2015, Alzheimer's Association Report 2015 Alzheimer's disease facts and figures, Alzheimer's Dement., 11, 332, 10.1016/j.jalz.2015.02.003 · DOI · Paper page
  12. Bagaitkar, 2012, Cotinine inhibits the pro-inflammatory response initiated by multiple cell surface Toll-like receptors in monocytic THP cells, Tob. Induc. Dis., 10, 18, 10.1186/1617-9625-10-18 · DOI
  13. Bales, 1998, The NF-kappaB/Rel family of proteins mediates Abeta-induced neurotoxicity and glial activation, Brain Res. Mol. Brain Res., 57, 63, 10.1016/S0169-328X(98)00066-7 · DOI · Paper page
  14. Barreto, 2015, Beneficial effects of nicotine, cotinine and its metabolites as potential agents for Parkinson's disease, Front. Aging Neurosci., 6, 340, 10.3389/fnagi.2014.00340 · DOI
  15. Beach, 1989, Patterns of gliosis in Alzheimer's disease and aging cerebrum, Glia, 2, 420, 10.1002/glia.440020605 · DOI · Paper page
  16. Benarroch, 2013, Microglia: Multiple roles in surveillance, circuit shaping, and response to injury, Neurology, 81, 1079, 10.1212/WNL.0b013e3182a4a577 · DOI · Paper page
  17. Bhattacharya, 2015, Nasal application of the galantamine pro-drug memogain slows down plaque deposition and ameliorates behavior in 5× familial Alzheimer's disease mice, J. Alzheimers Dis., 46, 123, 10.3233/JAD-142421 · DOI · Paper page
  18. Birks, 2000, Rivastigmine for Alzheimer's disease, Cochrane Database Syst. Rev., 2, CD001191
  19. Blain, 2000, Non-steroidal anti-inflammatory drugs with selectivity for cyclooxygenase-2 in Alzheimer's disease. Rationale and perspectives, Presse Med., 29, 267
  20. Boche, 2008, Consequence of Abeta immunization on the vasculature of human Alzheimer's disease brain, Brain, 131, 3299, 10.1093/brain/awn261 · DOI · Paper page
  21. Boutajangout, 2010, Immunotherapy targeting pathological tau prevents cognitive decline in a new tangle mouse model, J. Neurosci., 30, 16559, 10.1523/JNEUROSCI.4363-10.2010 · DOI · Paper page
  22. Brown, 2012, MG624, an alpha7-nAChR antagonist, inhibits angiogenesis via the Egr-1/FGF2 pathway, Angiogenesis, 15, 99, 10.1007/s10456-011-9246-9 · DOI
  23. Brun, 1986, Brain changes in dementia of Alzheimer's type relevant to new imaging diagnostic methods, Prog. Neuropsychopharmacol. Biol. Psychiatry, 10, 297, 10.1016/0278-5846(86)90009-6 · DOI
  24. Buckwalter, 2004, Modelling neuroinflammatory phenotypes in vivo, J. Neuroinflammation., 1, 10, 10.1186/1742-2094-1-10 · DOI
  25. Buttini, 1998, Novel role of human CD4 molecule identified in neurodegeneration, Nat. Med., 4, 441, 10.1038/nm0498-441 · DOI
  26. Carmeli, 2013, Demyelination in mild cognitive impairment suggests progression path to Alzheimer's disease, PLoS ONE, 8, e72759, 10.1371/journal.pone.0072759 · DOI · Paper page
  27. Carrasco, 2008, Prostaglandin receptor EP2 protects dopaminergic neurons against 6-OHDA-mediated low oxidative stress, Neurosci. Lett., 441, 44, 10.1016/j.neulet.2008.05.111 · DOI
  28. Carson, 2008, Genetic variation in the alpha 7 nicotinic acetylcholine receptor is associated with delusional symptoms in Alzheimer's disease, Neuromolecular. Med., 10, 377, 10.1007/s12017-008-8048-8 · DOI
  29. Chang, 2010, NeuroHIV and use of addictive substances, Int. Rev. Neurobiol., 118, 403, 10.1016/B978-0-12-801284-0.00013-0 · DOI
  30. Changeux, 1998, Allosteric receptors after 30 years, Neuron, 21, 959, 10.1016/S0896-6273(00)80616-9 · DOI · Paper page
  31. Changeux, 2005, Allosteric mechanisms of signal transduction, Science, 308, 1424, 10.1126/science.1108595 · DOI · Paper page
  32. Chen, 2006, alpha7 Nicotinic acetylcholine receptor as a target to rescue deficit in hippocampal LTP induction in beta-amyloid infused rats, Neuropharmacology, 50, 254, 10.1016/j.neuropharm.2005.09.018 · DOI
  33. Cohen, 2013, A transgenic Alzheimer rat with plaques, tau pathology, behavioral impairment, oligomeric abeta, and frank neuronal loss, J. Neurosci., 33, 6245, 10.1523/JNEUROSCI.3672-12.2013 · DOI · Paper page
  34. Craig, 2011, Revisiting the cholinergic hypothesis in the development of Alzheimer's disease, Neurosci. Biobehav. Rev., 35, 1397, 10.1016/j.neubiorev.2011.03.001 · DOI · Paper page
  35. Cudaback, 2014, Therapeutic implications of the prostaglandin pathway in Alzheimer's disease, Biochem. Pharmacol., 88, 565, 10.1016/j.bcp.2013.12.014 · DOI
  36. de la Torre, 2014, Phase 3 trials of solanezumab and bapineuzumab for Alzheimer's disease, N. Engl. J. Med., 370, 1459, 10.1056/NEJMc1402193 · DOI · Paper page
  37. De Simone, 2005, Activation of alpha7 nicotinic acetylcholine receptor by nicotine selectively up-regulates cyclooxygenase-2 and prostaglandin E2 in rat microglial cultures, J. Neuroinflammation, 2, 4, 10.1186/1742-2094-2-4 · DOI
  38. Dhib-Jalbut, 2006, Neurodegeneration and neuroprotection in multiple sclerosis and other neurodegenerative diseases, J. Neuroimmunol., 176, 198, 10.1016/j.jneuroim.2006.03.027 · DOI
  39. Dickson, 1993, Microglia and cytokines in neurological disease, with special reference to AIDS and Alzheimer's disease, Glia, 7, 75, 10.1002/glia.440070113 · DOI · Paper page
  40. Dineley, 2015, Nicotinic ACh receptors as therapeutic targets in CNS disorders, Trends Pharmacol. Sci., 36, 96, 10.1016/j.tips.2014.12.002 · DOI · Paper page
  41. Dore, 2006, GPCR antagonists as an alternative to COX-2 inhibitors: a case for the PGE2 EP1 receptor, Trends Pharmacol. Sci., 27, 458, 10.1016/j.tips.2006.07.001 · DOI
  42. Dunlop, 2009, Old and new pharmacology: positive allosteric modulation of the alpha7 nicotinic acetylcholine receptor by the 5-hydroxytryptamine(2B/C) receptor antagonist SB-206553 (3,5-dihydro-5-methyl-N-3-pyridinylbenzo[1,2-b:4,5-b′]di pyrrole-1(2H)-carboxamide), J. Pharmacol. Exp. Ther., 328, 766, 10.1124/jpet.108.146514 · DOI
  43. Echeverria, 2005, Stimulation of PGE receptors EP2 and EP4 protects cultured neurons against oxidative stress and cell death following beta-amyloid exposure, Eur. J. Neurosci., 22, 2199, 10.1111/j.1460-9568.2005.04427.x · DOI · Paper page
  44. Echeverria, 2012, Cotinine: a potential new therapeutic agent against Alzheimer's disease, CNS Neurosci. Ther., 18, 517, 10.1111/j.1755-5949.2012.00317.x · DOI
  45. Echeverria, 2011, Cotinine reduces amyloid-beta aggregation and improves memory in Alzheimer's disease mice, J. Alzheimers Dis., 24, 817, 10.3233/JAD-2011-102136 · DOI
  46. Farlow, 2012, Safety and biomarker effects of solanezumab in patients with Alzheimer's disease, Alzheimers Dement., 8, 261, 10.1016/j.jalz.2011.09.224 · DOI · Paper page
  47. Feldman, 2009, Analyses of mortality risk in patients with dementia treated with galantamine, Acta Neurol. Scand., 119, 22, 10.1111/j.1600-0404.2008.01047.x · DOI
  48. Feldman, 2009, Treatment with galantamine and time to nursing home placement in Alzheimer's disease patients with and without cerebrovascular disease, Int. J. Geriatr. Psychiatry, 24, 479, 10.1002/gps.2141 · DOI · Paper page
  49. Foster, 2001, Calcineurin links Ca2+ dysregulation with brain aging, J. Neurosci., 21, 4066, 10.1523/JNEUROSCI.21-11-04066.2001 · DOI · Paper page
  50. Fuxe, 1979, On the action of nicotine and cotinine on central 5-hydroxytryptamine neurons, Pharmacol. Biochem. Behav., 10, 671, 10.1016/0091-3057(79)90319-8 · DOI
  51. Galvis, 2006, Expression of nicotinic acetylcholine receptors on murine alveolar macrophages, J. Mol. Neurosci., 30, 107, 10.1385/JMN:30:1:107 · DOI
  52. Gatson, 2015, High therapeutic potential of positive allosteric modulation of alpha7 nAChRs in a rat model of traumatic brain injury: proof-of-concept, Brain Res. Bull., 112, 35, 10.1016/j.brainresbull.2015.01.008 · DOI
  53. Ghezzi, 2013, Disease-modifying drugs in Alzheimer's disease, Drug Des. Devel. Ther., 7, 1471
  54. Gorkiewicz, 2010, Matrix metalloproteinase-9 reversibly affects the time course of NMDA-induced currents in cultured rat hippocampal neurons, Hippocampus, 20, 1105, 10.1002/hipo.20736 · DOI
  55. Gotz, 2010, Animal models reveal role for tau phosphorylation in human disease, Biochim. Biophys. Acta, 1802, 860, 10.1016/j.bbadis.2009.09.008 · DOI
  56. Gotz, 2012, Alzheimer's disease models and functional genomics-How many needles are there in the haystack?, Front. Physiol., 3, 320, 10.3389/fphys.2012.00320 · DOI
  57. Guo, 2012, Nicotine dynamically modulates dopamine clearance in rat striatum in vivo, Neurochem. Int., 60, 355, 10.1016/j.neuint.2012.01.022 · DOI
  58. Hoozemans, 2003, Non-steroidal anti-inflammatory drugs and cyclooxygenase in Alzheimer's disease, Curr. Drug Targets, 4, 461, 10.2174/1389450033490902 · DOI · Paper page
  59. Horiuchi, 2012, Amyloid beta1–42 oligomer inhibits myelin sheet formation in vitro, Neurobiol. Aging, 33, 499, 10.1016/j.neurobiolaging.2010.05.007 · DOI
  60. Hu, 2015, Confirmatory population pharmacokinetic analysis for bapineuzumab phase 3 studies in patients with mild to moderate Alzheimer's disease, J. Clin. Pharmacol., 55, 221, 10.1002/jcph.393 · DOI
  61. Hurst, 2005, A novel positive allosteric modulator of the alpha7 neuronal nicotinic acetylcholine receptor: in vitro and in vivo characterization, J. Neurosci., 25, 4396, 10.1523/JNEUROSCI.5269-04.2005 · DOI · Paper page
  62. Inestrosa, 2013, Nicotine prevents synaptic impairment induced by amyloid-beta oligomers through alpha7-nicotinic acetylcholine receptor activation, Neuromol. Med., 15, 549, 10.1007/s12017-013-8242-1 · DOI
  63. Inglese, 2005, The relation between MRI measures of inflammation and neurodegeneration in multiple sclerosis, J. Neurol. Sci., 233, 15, 10.1016/j.jns.2005.03.001 · DOI
  64. Ishizawa, 2003, Co-localization of glycogen synthase kinase-3 with neurofibrillary tangles and granulovacuolar degeneration in transgenic mice, Am. J. Pathol., 163, 1057, 10.1016/S0002-9440(10)63465-7 · DOI
  65. Jones, 2012, Muscarinic and nicotinic acetylcholine receptor agonists and allosteric modulators for the treatment of schizophrenia, Neuropsychopharmacology, 37, 16, 10.1038/npp.2011.199 · DOI · Paper page
  66. Kamat, 2014, Astrocyte mediated MMP-9 activation in the synapse dysfunction: an implication in Alzheimer disease, Ther. Targets Neurol. Dis., 1, e243
  67. Kavanagh, 2011, Galantamine and behavior in Alzheimer disease: analysis of four trials, Acta Neurol. Scand., 124, 302, 10.1111/j.1600-0404.2011.01525.x · DOI
  68. Kavanagh, 2011, Long-term response to galantamine in relation to short-term efficacy data: pooled analysis in patients with mild to moderate Alzheimer's disease, Curr. Alzheimer Res., 8, 175, 10.2174/156720511795256044 · DOI
  69. Kavanagh, 2011, Long-term effects of galantamine on cognitive function in Alzheimer's disease: a large-scale international retrospective study, J. Alzheimers Dis., 27, 521, 10.3233/JAD-2011-110417 · DOI
  70. Kihara, 2004, Galantamine modulates nicotinic receptor and blocks Abeta-enhanced glutamate toxicity, Biochem. Biophys. Res. Commun., 325, 976, 10.1016/j.bbrc.2004.10.132 · DOI
  71. Kihara, 1998, Stimulation of alpha4beta2 nicotinic acetylcholine receptors inhibits beta-amyloid toxicity, Brain Res., 792, 331, 10.1016/S0006-8993(98)00138-3 · DOI · Paper page
  72. Kosenko, 2014, Pathogenesis of Alzheimer disease: role of oxidative stress, amyloid-beta peptides, systemic ammonia and erythrocyte energy metabolism, CNS Neurol. Disord. Drug Targets, 13, 112, 10.2174/18715273113126660130 · DOI · Paper page
  73. Lambracht-Washington, 2013, Anti-amyloid beta to tau—based immunization: developments in immunotherapy for Alzheimer disease, Immunotargets Ther., 2013, 105, 10.2147/ITT.S31428 · DOI
  74. Laske, 2014, Phase 3 trials of solanezumab and bapineuzumab for Alzheimer's disease, N. Engl. J. Med., 370, 1459, 10.1056/NEJMc1402193 · DOI · Paper page
  75. Lassmann, 2007, Multiple sclerosis: is there neurodegeneration independent from inflammation?, J. Neurol. Sci., 259, 3, 10.1016/j.jns.2006.08.016 · DOI
  76. LaVoie, 1985, Evaluation of the effects of cotinine and nicotine-N′-oxides on the development of tumors in rats initiated with N-[4-(5-nitro-2-furyl)-2-thiazolyl]formamide, J. Natl. Cancer Inst., 75, 1075
  77. Lee, 2015, Activated human microglia stimulate neuroblastoma cells to upregulate production of beta amyloid protein and tau: implications for Alzheimer's disease pathogenesis, Neurobiol. Aging, 36, 42, 10.1016/j.neurobiolaging.2014.07.024 · DOI
  78. Leiser, 2009, A cog in cognition: how the alpha 7 nicotinic acetylcholine receptor is geared towards improving cognitive deficits, Pharmacol. Ther., 122, 302, 10.1016/j.pharmthera.2009.03.009 · DOI · Paper page
  79. Li, 2014, Activation of alpha7 nicotinic acetylcholine receptor protects against oxidant stress damage through reducing vascular peroxidase-1 in a JNK signaling-dependent manner in endothelial cells, Cell Physiol. Biochem., 33, 468, 10.1159/000358627 · DOI
  80. Lieberman, 2013, A randomized exploratory trial of an alpha-7 nicotinic receptor agonist (TC-5619) for cognitive enhancement in schizophrenia, Neuropsychopharmacology, 38, 968, 10.1038/npp.2012.259 · DOI · Paper page
  81. Liu, 2014, T cells promote the regeneration of neural precursor cells in the hippocampus of Alzheimer's disease mice, Neural Regen. Res., 9, 1541, 10.4103/1673-5374.139481 · DOI
  82. Livingstone, 2010, Glutamate-dopamine crosstalk in the rat prefrontal cortex is modulated by Alpha7 nicotinic receptors and potentiated by PNU-120596, J. Mol. Neurosci., 40, 172, 10.1007/s12031-009-9232-5 · DOI
  83. Lloyd, 2001, Depression in late life, cognitive decline and white matter pathology in two clinico-pathologically investigated cases, Int. J. Geriatr. Psychiatry, 16, 281, 10.1002/gps.328 · DOI
  84. Lok, 2012, Neuregulin-1 effects on endothelial and blood–brain-barrier permeability after experimental injury, Transl. Stroke Res., 3, S119, 10.1007/s12975-012-0157-x · DOI
  85. Lopez-Hernandez, 2009, Positive modulation of alpha7 nAChR responses in rat hippocampal interneurons to full agonists and the alpha7-selective partial agonists, 4OH-GTS-21 and S 24795, Neuropharmacology, 56, 821, 10.1016/j.neuropharm.2009.01.011 · DOI
  86. Luber-Narod, 1988, Immune system associated antigens expressed by cells of the human central nervous system, Neurosci. Lett., 94, 17, 10.1016/0304-3940(88)90263-7 · DOI
  87. Ludwig, 2010, Localization by site-directed mutagenesis of a galantamine binding site on alpha7 nicotinic acetylcholine receptor extracellular domain, J. Recept Signal Transduct. Res., 30, 469, 10.3109/10799893.2010.505239 · DOI
  88. Luo, 2007, Glia-dependent TGF-beta signaling, acting independently of the TH17 pathway, is critical for initiation of murine autoimmune encephalomyelitis, J. Clin. Invest., 117, 3306, 10.1172/JCI31763 · DOI · Paper page
  89. Maelicke, 2010, Memogain is a galantamine pro-drug having dramatically reduced adverse effects and enhanced efficacy, J. Mol. Neurosci., 40, 135, 10.1007/s12031-009-9269-5 · DOI
  90. Majumdar, 2008, Degradation of fibrillar forms of Alzheimer's amyloid beta-peptide by macrophages, Neurobiol. Aging, 29, 707, 10.1016/j.neurobiolaging.2006.12.001 · DOI
  91. Maldifassi, 2014, A new IRAK-M-mediated mechanism implicated in the anti-inflammatory effect of nicotine via alpha7 nicotinic receptors in human macrophages, PLoS ONE, 9, e108397, 10.1371/journal.pone.0108397 · DOI
  92. Mancardi, 1983, Fibrous astrocytes in Alzheimer's disease and senile dementia of Alzheimer's type, Acta Neuropathol., 61, 76, 10.1007/BF00688390 · DOI
  93. Marosova, 2014, How can viruses influence the neuroinflammation and neurodegeneration in the aged human brain, Acta Virol., 57, 273
  94. Martelli, 2014, The cholinergic anti-inflammatory pathway: a critical review, Auton Neurosci., 182, 65, 10.1016/j.autneu.2013.12.007 · DOI · Paper page
  95. McCarty, 2009, Cell adhesion and signaling networks in brain neurovascular units, Curr. Opin. Hematol., 16, 209, 10.1097/MOH.0b013e32832a07eb · DOI
  96. McGeer, 2010, Neuroinflammation in Alzheimer's disease and mild cognitive impairment: a field in its infancy, J. Alzheimers Dis., 19, 355, 10.3233/JAD-2010-1219 · DOI · Paper page
  97. McGeer, 1989, Immune system response in Alzheimer's disease, Can. J. Neurol. Sci., 16, 516, 10.1017/S0317167100029863 · DOI · Paper page
  98. McGeer, 2000, Autotoxicity and Alzheimer disease, Arch. Neurol., 57, 789, 10.1001/archneur.57.6.789 · DOI · Paper page
  99. McGeer, 2001, Inflammation, autotoxicity and Alzheimer disease, Neurobiol. Aging, 22, 799, 10.1016/S0197-4580(01)00289-5 · DOI · Paper page
  100. McGeer, 2002, Innate immunity, local inflammation, and degenerative disease, Sci. Aging Knowledge Environ., 2002, re3, 10.1126/sageke.2002.29.re3 · DOI · Paper page
  101. McGeer, 2011, History of innate immunity in neurodegenerative disorders, Front. Pharmacol., 2, 77, 10.3389/fphar.2011.00077 · DOI · Paper page
  102. McGeer, 2013, Targeting microglia for the treatment of Alzheimer's disease, Expert Opin. Ther. Targets, 1
  103. McGeer, 2006, Inflammation, anti-inflammatory agents and Alzheimer disease: the last 12 years, J. Alzheimers Dis., 9, 271, 10.3233/JAD-2006-9S330 · DOI · Paper page
  104. Michaluk, 2007, Matrix metalloproteinase-9 in glutamate-dependent adult brain function and dysfunction, Cell Death Differ., 14, 1255, 10.1038/sj.cdd.4402141 · DOI
  105. Michaluk, 2007, Beta-dystroglycan as a target for MMP-9, in response to enhanced neuronal activity, J. Biol. Chem., 282, 16036, 10.1074/jbc.M700641200 · DOI · Paper page
  106. Miguel-Alvarez, 2015, Non-steroidal anti-inflammatory drugs as a treatment for Alzheimer's disease: a systematic review and meta-analysis of treatment effect, Drugs Aging, 32, 139, 10.1007/s40266-015-0239-z · DOI · Paper page
  107. Miklossy, 2006, Role of ICAM-1 in persisting inflammation in Parkinson disease and MPTP monkeys, Exp. Neurol., 197, 275, 10.1016/j.expneurol.2005.10.034 · DOI · Paper page
  108. Mitew, 2010, Focal demyelination in Alzheimer's disease and transgenic mouse models, Acta Neuropathol., 119, 567, 10.1007/s00401-010-0657-2 · DOI · Paper page
  109. Miyauchi, 2012, Toll-like receptor (TLR) 3 as a surrogate sensor of retroviral infection in human cells, Biochem. Biophys. Res. Commun., 424, 519, 10.1016/j.bbrc.2012.06.148 · DOI
  110. Monod, 1965, On the nature of allosteric transitions: a plausible model, J. Mol. Biol., 12, 88, 10.1016/S0022-2836(65)80285-6 · DOI · Paper page
  111. Mushtaq, 2015, Alzheimer's disease and type 2 diabetes via chronic inflammatory mechanisms, Saudi J. Biol. Sci., 22, 4, 10.1016/j.sjbs.2014.05.003 · DOI · Paper page
  112. Nacmias, 2014, Genetics of Alzheimer's disease and frontotemporal dementia, Curr. Mol. Med., 10.2174/1566524014666141010152143 · DOI
  113. Nagai, 1983, Choline acetyltransferase immunohistochemistry in brains of Alzheimer's disease patients and controls, Neurosci. Lett., 36, 195, 10.1016/0304-3940(83)90264-1 · DOI · Paper page
  114. Najem, 2014, Insulin resistance, neuroinflammation, and Alzheimer's disease, Rev. Neurosci., 25, 509, 10.1515/revneuro-2013-0050 · DOI · Paper page
  115. Nimmerjahn, 2009, Astrocytes going live: advances and challenges, J. Physiol., 587, 1639, 10.1113/jphysiol.2008.167171 · DOI · Paper page
  116. Nimmerjahn, 2005, Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo, Science, 308, 1314, 10.1126/science.1110647 · DOI · Paper page
  117. Nordberg, 2002, Chronic nicotine treatment reduces beta-amyloidosis in the brain of a mouse model of Alzheimer's disease (APPsw), J. Neurochem., 81, 655, 10.1046/j.1471-4159.2002.00874.x · DOI · Paper page
  118. Norris, 2002, Calcineurin enhances L-type Ca(2+) channel activity in hippocampal neurons: increased effect with age in culture, Neuroscience, 110, 213, 10.1016/S0306-4522(01)00574-7 · DOI
  119. Ono, 2002, Nicotine breaks down preformed Alzheimer's beta-amyloid fibrils in vitro, Biol. Psychiatry, 52, 880, 10.1016/S0006-3223(02)01417-8 · DOI
  120. Ono, 2006, The development of preventives and therapeutics for Alzheimer's disease that inhibit the formation of beta-amyloid fibrils (fAbeta), as well as destabilize preformed fAbeta, Curr. Pharm. Des., 12, 4357, 10.2174/138161206778793010 · DOI · Paper page
  121. Overmyer, 1999, Astrogliosis and the ApoE genotype. an immunohistochemical study of postmortem human brain tissue, Dement. Geriatr. Cogn. Disord., 10, 252, 10.1159/000017128 · DOI · Paper page
  122. Palma, 1998, Effects of Zn2+ on wild and mutant neuronal alpha7 nicotinic receptors, Proc. Natl. Acad. Sci. U.S.A., 95, 10246, 10.1073/pnas.95.17.10246 · DOI
  123. Panza, 2014, Amyloid-based immunotherapy for Alzheimer's disease in the time of prevention trials: the way forward, Expert. Rev. Clin. Immunol., 10, 405, 10.1586/1744666X.2014.883921 · DOI
  124. Parachikova, 2007, Inflammatory changes parallel the early stages of Alzheimer disease, Neurobiol. Aging, 28, 1821, 10.1016/j.neurobiolaging.2006.08.014 · DOI · Paper page
  125. Paresce, 1997, Slow degradation of aggregates of the Alzheimer's disease amyloid beta-protein by microglial cells, J. Biol. Chem., 272, 29390, 10.1074/jbc.272.46.29390 · DOI · Paper page
  126. Paris, 2013, Anti-inflammatory activity of anatabine via inhibition of STAT3 phosphorylation, Eur. J. Pharmacol., 698, 145, 10.1016/j.ejphar.2012.11.017 · DOI
  127. Patel, 2014, Cotinine halts the advance of Alzheimer's disease-like pathology and associated depressive-like behavior in Tg6799 mice, Front. Aging Neurosci., 6, 162, 10.3389/fnagi.2014.00162 · DOI
  128. Paulson, 2008, Amyloid plaque and neurofibrillary tangle pathology in a regulatable mouse model of Alzheimer's disease, Am. J. Pathol., 173, 762, 10.2353/ajpath.2008.080175 · DOI
  129. Pavlov, 2007, Selective alpha7-nicotinic acetylcholine receptor agonist GTS-21 improves survival in murine endotoxemia and severe sepsis, Crit. Care Med., 35, 1139, 10.1097/01.CCM.0000259381.56526.96 · DOI · Paper page
  130. Perry, 2000, Oxidative damage in Alzheimer's disease: the metabolic dimension, Int. J. Dev. Neurosci., 18, 417, 10.1016/S0736-5748(00)00006-X · DOI · Paper page
  131. Pooler, 2013, Tau-amyloid interactions in the rTgTauEC model of early Alzheimer's disease suggest amyloid-induced disruption of axonal projections and exacerbated axonal pathology, J. Comp. Neurol., 521, 4236, 10.1002/cne.23411 · DOI · Paper page
  132. Posadas, 2013, Nicotinic receptors in neurodegeneration, Curr. Neuropharmacol., 11, 298, 10.2174/1570159X11311030005 · DOI
  133. Raivich, 2005, Like cops on the beat: the active role of resting microglia, Trends Neurosci., 28, 571, 10.1016/j.tins.2005.09.001 · DOI · Paper page
  134. Rehani, 2008, Cotinine-induced convergence of the cholinergic and PI3 kinase-dependent anti-inflammatory pathways in innate immune cells, Biochim. Biophys. Acta, 1783, 375, 10.1016/j.bbamcr.2007.12.003 · DOI
  135. Rodriguez, 2009, Astroglia in dementia and Alzheimer's disease, Cell Death Differ., 16, 378, 10.1038/cdd.2008.172 · DOI · Paper page
  136. Rogers, 1988, Expression of immune system-associated antigens by cells of the human central nervous system: relationship to the pathology of Alzheimer's disease, Neurobiol. Aging, 9, 339, 10.1016/S0197-4580(88)80079-4 · DOI · Paper page
  137. Rosas-Ballina, 2009, The selective alpha7 agonist GTS-21 attenuates cytokine production in human whole blood and human monocytes activated by ligands for TLR2, TLR3, TLR4, TLR9, and RAGE, Mol. Med., 15, 195, 10.2119/molmed.2009.00039 · DOI · Paper page
  138. Rossor, 1983, Focal changes in Alzheimer's disease and cholinergic hypothesis, Lancet, 2, 465, 10.1016/S0140-6736(83)90441-5 · doi:10.1016/s0140-6736(83)90441-5
  139. Rostasy, 2005, Inflammation and neuroaxonal injury in multiple sclerosis and AIDS dementia complex: implications for neuroprotective treatment, Neuropediatrics, 36, 230, 10.1055/s-2005-865864 · DOI
  140. Roth, 2005, Oligodendrocytes damage in Alzheimer's disease: beta amyloid toxicity and inflammation, Biol. Res., 38, 381, 10.4067/S0716-97602005000400011 · DOI
  141. Saez, 2006, Production of nerve growth factor by beta-amyloid-stimulated astrocytes induces p75NTR-dependent tau hyperphosphorylation in cultured hippocampal neurons, J. Neurosci. Res., 84, 1098, 10.1002/jnr.20996 · DOI · Paper page
  142. Saez, 2004, Astrocytic nitric oxide triggers tau hyperphosphorylation in hippocampal neurons, In Vivo, 18, 275
  143. Saiga, 2012, Innate immune effectors in mycobacterial infection, Clin. Dev. Immunol., 2011, 347594
  144. Salomon, 1996, Nicotine inhibits amyloid formation by the beta-peptide, Biochemistry, 35, 13568, 10.1021/bi9617264 · DOI · Paper page
  145. Samochocki, 2003, Galantamine is an allosterically potentiating ligand of neuronal nicotinic but not of muscarinic acetylcholine receptors, J. Pharmacol. Exp. Ther., 305, 1024, 10.1124/jpet.102.045773 · DOI · Paper page
  146. Samochocki, 2000, Galantamine is an allosterically potentiating ligand of the human alpha4/beta2 nAChR, Acta Neurol. Scand. Suppl., 176, 68, 10.1034/j.1600-0404.2000.00310.x · DOI · Paper page
  147. Seo, 2012, Neurovascular matrix metalloproteinases and the blood–brain barrier, Curr. Pharm. Des., 18, 3645, 10.2174/138161212802002742 · DOI · Paper page
  148. Sha, 2014, Active immunotherapy facilitates Abeta plaque removal following through microglial activation without obvious T cells infiltrating the CNS, J. Neuroimmunol., 274, 62, 10.1016/j.jneuroim.2014.06.008 · DOI
  149. Shi, 2012, Inflammatory prostaglandin E2 signaling in a mouse model of Alzheimer disease, Ann. Neurol., 72, 788, 10.1002/ana.23677 · DOI · Paper page
  150. Simard, 2006, Neuroprotective properties of the innate immune system and bone marrow stem cells in Alzheimer's disease, Mol. Psychiatry, 11, 327, 10.1038/sj.mp.4001809 · DOI
  151. Srivareerat, 2011, Chronic nicotine restores normal Abeta levels and prevents short-term memory and E-LTP impairment in Abeta rat model of Alzheimer's disease, Neurobiol. Aging, 32, 834, 10.1016/j.neurobiolaging.2009.04.015 · DOI
  152. Streit, 2014, Human CNS immune senescence and neurodegeneration, Curr. Opin. Immunol., 29, 93, 10.1016/j.coi.2014.05.005 · DOI · Paper page
  153. Struble, 1982, Cholinergic innervation in neuritic plaques, Science, 216, 413, 10.1126/science.6803359 · DOI · Paper page
  154. Suzuki, 2006, Microglial alpha7 nicotinic acetylcholine receptors drive a phospholipase C/IP3 pathway and modulate the cell activation toward a neuroprotective role, J. Neurosci. Res., 83, 1461, 10.1002/jnr.20850 · DOI · Paper page
  155. Takeda, 2001, Roles of Toll-like receptors in innate immune responses, Genes Cells, 6, 733, 10.1046/j.1365-2443.2001.00458.x · DOI · Paper page
  156. Takeda, 2004, TLR signaling pathways, Semin Immunol., 16, 3, 10.1016/j.smim.2003.10.003 · DOI · Paper page
  157. Takeda, 2003, Toll-like receptors, Annu. Rev. Immunol., 21, 335, 10.1146/annurev.immunol.21.120601.141126 · DOI · Paper page
  158. Takeuchi, 1999, Differential roles of TLR2 and TLR4 in recognition of gram-negative and gram-positive bacterial cell wall components, Immunity, 11, 443, 10.1016/S1074-7613(00)80119-3 · DOI · Paper page
  159. Takeuchi, 1999, TLR6: A novel member of an expanding toll-like receptor family, Gene, 231, 59, 10.1016/S0378-1119(99)00098-0 · DOI · Paper page
  160. Terry, 2015, R-(+) and s-(−) isomers of cotinine augment cholinergic responses in vitro and in vivo, J. Pharmacol. Exp. Ther., 352, 405, 10.1124/jpet.114.219881 · DOI
  161. Thomsen, 2012, The alpha7 nicotinic acetylcholine receptor ligands methyllycaconitine, NS6740 and GTS-21 reduce lipopolysaccharide-induced TNF-alpha release from microglia, J. Neuroimmunol., 251, 65, 10.1016/j.jneuroim.2012.07.006 · DOI
  162. Uteshev, 2002, Activation and inhibition of native neuronal alpha-bungarotoxin-sensitive nicotinic ACh receptors, Brain Res., 948, 33, 10.1016/S0006-8993(02)02946-3 · DOI
  163. Uteshev, 2003, Regulation of neuronal function by choline and 4OH-GTS-21 through alpha 7 nicotinic receptors, J Neurophysiol, 89, 1797, 10.1152/jn.00943.2002 · DOI · Paper page
  164. Velez-Fort, 2009, Functional alpha 7-containing nicotinic receptors of NG2-expressing cells in the hippocampus, Glia, 57, 1104, 10.1002/glia.20834 · DOI
  165. Villoslada, 2008, Immunotherapy for neurological diseases, Clin. Immunol., 128, 294, 10.1016/j.clim.2008.04.003 · DOI
  166. Wang, 2012, Multiple diffusivities define white matter degeneration in amnestic mild cognitive impairment and Alzheimer's disease, J. Alzheimers Dis., 30, 423, 10.3233/JAD-2012-111304 · DOI
  167. White, 2005, Differential effects of oligomeric and fibrillar amyloid-beta 1-42 on astrocyte-mediated inflammation, Neurobiol Dis, 18, 459, 10.1016/j.nbd.2004.12.013 · DOI · Paper page
  168. Whitehouse, 1986, Nicotinic acetylcholine binding sites in Alzheimer's disease, Brain Res., 371, 146, 10.1016/0006-8993(86)90819-X · DOI · Paper page
  169. Whitehouse, 1988, Reductions in [3H]nicotinic acetylcholine binding in Alzheimer's disease and Parkinson's disease: an autoradiographic study, Neurology, 38, 720, 10.1212/WNL.38.5.720 · DOI · Paper page
  170. Whitman, 2004, Oligodendrocyte degeneration in AD, Neurobiol. Aging, 25, 33, 10.1016/j.neurobiolaging.2003.06.001 · DOI
  171. Williams, 2012, Intrinsically low open probability of alpha7 nicotinic acetylcholine receptors can be overcome by positive allosteric modulation and serum factors leading to the generation of excitotoxic currents at physiological temperatures, Mol. Pharmacol., 82, 746, 10.1124/mol.112.080317 · DOI
  172. Williams, 2011, Positive allosteric modulators as an approach to nicotinic acetylcholine receptor-targeted therapeutics: advantages and limitations, Biochem. Pharmacol., 82, 915, 10.1016/j.bcp.2011.05.001 · DOI · Paper page
  173. Winterer, 2013, Allosteric alpha-7 nicotinic receptor modulation and P50 sensory gating in schizophrenia: a proof-of-mechanism study, Neuropharmacology, 64, 197, 10.1016/j.neuropharm.2012.06.040 · DOI
  174. Wyss-Coray, 2005, Killing pain, killing neurons?, Nat. Med., 11, 472, 10.1038/nm0505-472 · DOI
  175. Wyss-Coray, 2001, Key signaling pathways regulate the biological activities and accumulation of amyloid-beta, Neurobiol. Aging, 22, 967, 10.1016/S0197-4580(01)00305-0 · DOI
  176. Wyss-Coray, 2000, Ibuprofen, inflammation and Alzheimer disease, Nat. Med., 6, 973, 10.1038/79661 · DOI
  177. Xia, 2015, Pseudophosphorylation of Tau at distinct epitopes or the presence of the P301L mutation targets the microtubule-associated protein Tau to dendritic spines, Biochim. Biophys. Acta, 1852, 913, 10.1016/j.bbadis.2014.12.017 · DOI
  178. Xu, 2014, Amyloid precursor protein at node of Ranvier modulates nodal formation, Cell Adhesion Migr., 8, 396, 10.4161/cam.28802 · DOI
  179. Yong, 2010, Promoting remyelination by reducing an inhibitory microenvironment, Rinsho Shinkeigaku, 50, 869, 10.5692/clinicalneurol.50.869 · DOI
  180. Yong, 2010, The interplay between the immune and central nervous systems in neuronal injury, Neurology 74 Suppl, 1, S9
  181. Young, 2013, Evaluating the role of the alpha-7 nicotinic acetylcholine receptor in the pathophysiology and treatment of schizophrenia, Biochem. Pharmacol., 86, 1122, 10.1016/j.bcp.2013.06.031 · DOI · Paper page
  182. Zamani, 2001, Nicotine and its interaction with beta-amyloid protein: a short review, Biol. Psychiatry, 49, 221, 10.1016/S0006-3223(00)01108-2 · DOI
  183. Zandi, 2002, Reduced incidence of AD with NSAID but not H2 receptor antagonists: the Cache County Study, Neurology, 59, 880, 10.1212/WNL.59.6.880 · DOI · Paper page

Cited by

See all 91

Metadata

Authors
Echeverria, V., Yarkov, A., & Aliev, G.
Venue
Progress in Neurobiology
Publisher
Elsevier BV
Published
2016-09
Volume
144
Pages
142-157
ISSN
0301-0082 (ISSN-L)
OpenAlex
W2234380999
Cited by
91
References
63
FWCI
6.17
Type
journal article
Language
en
Open access
green
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Funders
University San Sebastian, Chile (1150194)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Positive modulators of the α7 nicotinic receptor against neuroinflammation and cognitive impairment in Alzheimer's disease. https://app.cochat.ai/papers/10.1016/j.pneurobio.2016.01.002
The paper
Echeverria, V., Yarkov, A., & Aliev, G. (2016). Positive modulators of the α7 nicotinic receptor against neuroinflammation and cognitive impairment in Alzheimer's disease. Progress in Neurobiology. https://doi.org/10.1016/j.pneurobio.2016.01.002

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.